Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

@article{Maio2005TryingTC,
  title={Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.},
  author={Massimo Di Maio and Cesare Gridelli and Nicola Normanno and Francesco Perrone and Fortunato Ciardiello},
  journal={Journal of cellular physiology},
  year={2005},
  volume={205 3},
  pages={
          355-63
        }
}
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown promising activity in patients with non-small cell lung cancer (NSCLC). Gefitinib has been the first of these drugs to be licensed for third-line treatment of advanced NSCLC patients. More recently, erlotinib has been shown to be more effective than placebo in increasing overall survival (OAS) and has been approved for NSCLC patients after failure of chemotherapy. However, a large body of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations

Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2006
View 1 Excerpt